A Phase 3 interventional study of Beclomethasone dipropionate and Placebo in Asthma, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 131 sites in 4 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-11-09.
Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies testing beclomethasone in Asthma — none open to participants now, none under way, none of them phase 3. Beclomethasone · Asthma.
Among the 40 studies testing beclomethasone in Asthma, this one is the 3rd largest by enrollment, is one of 5 that started in 2013, is one of 20 in phase 3, and was the 25th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →None of the 40 studies testing beclomethasone in Asthma is open now. The open studies under Asthma, anywhere →
Beclomethasone: first FDA approval 1976 (VANCERIL), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 22 · Phase 4 9
First in 1995; this study’s year is marked. 5 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,113 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 67 across the 40 interventional studies. Of the 35 that completed or were terminated, 14 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 40 have an industry lead sponsor. The 10 most frequent:
This study is registered under Teva Branded Pharmaceutical Products R&D, Inc., one of the names counted as Teva Pharmaceutical Industries, Ltd.. Under that name alone:
Teva Branded Pharmaceutical Products R&D, Inc. is the lead sponsor of 206 studies on the registry; none are open to participants now.
Of its 49 completed or terminated interventional studies of FDA-regulated products, 47 (96%) have results posted.
54 studies in Asthma by Teva Pharmaceutical Industries, Ltd.: none open now, 1 under way, 1 of them phase 3. Of 52 finished, 36 (69%) have results posted.
Among the 54 studies in Asthma by Teva Pharmaceutical Industries, Ltd., this one is the 4th largest by enrollment of the 51 interventional ones that give a count, is one of 8 that started in 2013, is one of 30 in phase 3, and was the 26th registered.
Teva Pharmaceutical Industries, Ltd.’s Asthma studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 40 studies testing beclomethasone in Asthma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Teva Pharmaceutical Industries, Ltd.’s 54 in Asthma:
This tab as a report to print or save as PDF → With an account.
This is a Phase 3, randomized, placebo-controlled, double-blind,double-dummy, parallel-group, 12-week study in male and female patients, 12 years of age and older, with persistent asthma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Beclomethasone dipropionate (BDP) via breath-actuated inhaler (BAI) twice daily.
Drug: Beclomethasone dipropionate · Drug: Placebo · Drug: Albuterol/salbutamol
Beclomethasone dipropionate (BDP) via breath-actuated inhaler (BAI) twice daily.
Drug: Beclomethasone dipropionate · Drug: Placebo · Drug: Albuterol/salbutamol
Beclomethasone dipropionate (BDP) via metered dose inhaler (MDI) twice daily.
Drug: Beclomethasone dipropionate · Drug: Placebo · Drug: Albuterol/salbutamol
Beclomethasone dipropionate (BDP) via metered dose inhaler (MDI) twice daily.
Drug: Beclomethasone dipropionate · Drug: Placebo · Drug: Albuterol/salbutamol
Placebo breath-actuated inhaler (BAI), twice daily. Plus placebo metered dose inhaler (MDI), twice daily.
Drug: Placebo · Drug: Albuterol/salbutamol
Also known as: BDP
Drug page: Albuterol
Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI \[90 mcg ex-actuator\] or equivalent) for use on an as-needed basis for the immediate relief of asthma symptoms throughout the treatment period.
Also known as: bronchodilators
Standardized Baseline-adjusted Trough Morning Forced Expiratory Volume in 1 Second (FEV1) Area Under the Effect Curve From Time 0 to 12 Weeks (AUEC(0-12wk) )
Trough morning FEV1 measurements were taken pre-dose and pre-rescue bronchodilator treatment for asthma. The baseline pulmonary function measurement was defined as the measurement obtained at randomization visit (Day 1). Pulmonary function measurements (including FEV1) were obtained electronically by spirometry. All pulmonary function test data were submitted to a central reading center for evaluation. The highest FEV1 value from 3 acceptable and 2 repeatable maneuvers (maximum of 5 attempts) was used. Baseline-adjusted FEV1 AUEC(0-12wk) were calculated using the trapezoidal rule. The standardized baseline-adjusted FEV1 AUEC(0-12 wk) accommodates participants who dropped out of the study. Baseline-adjusted FEV1 AUEC(0-t weeks)/t, where t =12 weeks for patients who complete the FEV1 assessment at Week 12. For participants who dropped out early, t \<12 weeks (2, 4, or 8 weeks).
Time frame: Day 1 (baseline), Weeks 2, 4, 8, 12
Change From Baseline in Weekly Average of Daily Trough Morning Peak Expiratory Flow (PEF) Over the 12-week Treatment Period Using a Mixed Model for Repeated Measures (MMRM)
A hand-held peak flow meter was provided to patients at the screening visit and used to determine the morning and evening PEF throughout the course of the study. Daily trough morning PEF assessments were taken pre-dose and pre-rescue bronchodilator over the 12-week treatment period. The patient recorded the highest value of 3 measurements obtained in the morning and evening in the patient diary. Baseline in trough morning PEF is defined as the average of recorded trough morning PEF assessments over the 7-day window before randomization, including the morning assessment on Day 1 before randomization. Weekly average PEF data was generated using 7-day windows based on analysis days (before the first dose of double-blind study treatment). PEF over the 12 week treatment period was performed using a mixed-model for repeated measures (MMRM) with effects due to baseline weekly average of daily trough morning PEF, sex, age, treatment, time, and time by treatment interaction.
Time frame: Baseline: Days -6 to Day 1 (pre-randomization), Treatment: Day 2 to Week 12
Change From Baseline in Weekly Average of Daily Evening Peak Expiratory Flow (PEF) Over the 12-week Treatment Period Using a Mixed Model for Repeated Measures (MMRM)
A hand-held peak flow meter was provided to patients at the screening visit and used to determine the morning and evening PEF throughout the course of the study. The patient recorded the highest value of 3 measurements obtained in the morning and evening in the patient diary. Baseline in evening PEF is defined as the average of recorded evening PEF assessments over the 7-day window before randomization. Weekly average PEF data was generated using 7-day windows based on analysis days (after the first dose of double-blind study treatment). PEF over the 12 week treatment period was performed using a mixed-model for repeated measures (MMRM) with effects due to baseline weekly average of daily evening peak PEF, sex, age, treatment, time, and time by treatment interaction.
Time frame: Baseline: Days -7 to Day -1, Treatment: Day 1 to Week 12
Change From Baseline in the Weekly Average of Total Daily (24-hour) Use of Albuterol/Salbutamol Inhalation Aerosol (Number of Inhalations) Over Weeks 1-12 Using a Mixed Model for Repeated Measures (MMRM)
Change from baseline in the use of rescue medication, albuterol/salbutamol, during the treatment period offers an indication of asthma control. Baseline was defined as the average of recorded daily usage of albuterol/salbutamol inhalation aerosol over the 7 days prior to the first dose of double-blind study treatment, including the morning usage at the randomization visit. Weekly average rescue medication data was generated using 7-day windows based on analysis days (after the first dose of double-blind study treatment). Weekly average over the 12 week treatment period was performed using a mixed-model for repeated measures (MMRM) with effects due to baseline value, sex, age, time, treatment, and time-by-treatment interaction.
Time frame: Baseline: Days -6 to Day 1 (pre-randomization), Treatment: Day 1 to Week 12
Change From Baseline in the Weekly Average of the Total Daily Asthma Symptom Score Over Weeks 1-12 Using a Mixed Model for Repeated Measures (MMRM)
Asthma symptom scores are recorded in the patient's diary each morning and each evening before determining PEF and before administration of study or rescue medications. The Daytime Symptom Score (determined in the evening) has a range from 0=No symptoms during the day to 5=Symptoms so severe that I could not go to work or perform normal daily activities. The Nighttime Symptom Score (determined in the morning) has a range from 0=No symptoms during the night to 4=Symptoms so severe that I did not sleep at all. The total daily asthma symptom score is the average of the daytime and the nighttime scores (full scale is 0 - 4.5). The total daily asthma symptom score is missing if either the daytime or nighttime score is missing. Baseline was the average of recorded daily asthma symptom scores over 7 days prior to the first dose of study treatment. The weekly average was the sum of total daily asthma symptom scores over the 7 days divided by the number of non-missing assessments.
Time frame: Days -6 to Day 1 (pre-randomization), Treatment: Day 1 to Week 12
Kaplan-Meier Estimates for Time to Withdrawal From Study Treatment Due to Meeting Stopping Criteria for Worsening Asthma
Time to withdrawal due to meeting stopping criteria is defined as number of days elapsed from the date of the first dose of double-blind study treatment to the date of withdrawal due to meeting stopping criteria. Stopping criteria are: * FEV1 as measured at the study center is below the FEV1 stability limit value calculated at RV. * Based upon review of patient diary data, the patient has experienced any of the following during any 7-day period: * 4+ days in which the highest (of 3 efforts) am PEF fall below the PEF stability limit calculated when randomized. The patient meets with the investigator who determines whether the FEV1 is consistent with worsening asthma; * 3+ days in which 12+ inhalations/day of rescue medication were used * 2+ days in which the patient experienced a nighttime asthma symptom score of more than 2 * Clinical asthma exacerbation requiring (for example) the use of systemic corticosteroids, or the emergency room or hospitalization.
Time frame: Day 1 - Week 12
Number of Participants Withdrawn From Study Due to Meeting Stopping Criteria for Worsening Asthma During the 12-Week Treatment Period
A count of participants who were withdrawn from the study due to meeting stopping criteria. Alert criteria for individual patients with worsening asthma were designed to ensure patient safety. The investigator determined whether the patient's overall clinical picture is consistent with worsening asthma and if the patient should be withdrawn from study drug treatment (but not the study) and be placed on appropriate asthma therapy in the interest of patient safety. An example of alert criteria is: * FEV1 as measured at the study center is below the FEV1 stability limit value calculated at randomization visit (Day 1). * Other criteria as defined in the protocol.
Time frame: Treatment period: Day 1 up to Week 12
For this study, 125 sites were activated, 115 sites screened at least 1 patient (91 centers in the United States, 10 centers in Germany, 10 centers in Hungary, and 4 centers in Poland), and 97 sites randomized at least 1 patient.
| Milestone | Consented Patients - Standard ICS and Placebo | Placebo BAI and MDI | BDP 320 mcg BAI | BDP 640 mcg BAI | BDP 320 mcg MDI | BDP 640 mcg MDI |
|---|---|---|---|---|---|---|
| Started | 1113 | 0 | 0 | 0 | 0 | 0 |
| Completed | 701 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 412 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 29 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Inclusion criteria not met | 312 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Exclusion criteria met | 30 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 14 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Enrollment closed | 26 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Consented Patients - Standard ICS and Placebo | Placebo BAI and MDI | BDP 320 mcg BAI | BDP 640 mcg BAI | BDP 320 mcg MDI | BDP 640 mcg MDI |
|---|---|---|---|---|---|---|
| Started | 701 | 0 | 0 | 0 | 0 | 0 |
| Completed | 532 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 169 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 4 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 17 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Inclusion criteria not met | 38 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Exclusion criteria met | 8 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Randomization criteria not met | 85 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Various administrative reasons | 17 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Consented Patients - Standard ICS and Placebo | Placebo BAI and MDI | BDP 320 mcg BAI | BDP 640 mcg BAI | BDP 320 mcg MDI | BDP 640 mcg MDI |
|---|---|---|---|---|---|---|
| Started | 0 | 106 | 106 | 106 | 107 | 107 |
| Full analysis set | 0 | 106 | 104 | 106 | 106 | 107 |
| Completed | 0 | 84 | 100 | 99 | 96 | 104 |
| Not completed | 0 | 22 | 6 | 7 | 11 | 3 |
| Withdrew: Protocol deviation | 0 | 2 | 0 | 1 | 3 | 1 |
| Withdrew: Lack of efficacy | 0 | 14 | 3 | 2 | 5 | 1 |
| Withdrew: Non-compliance | 0 | 1 | 0 | 1 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 2 | 3 | 1 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 3 | 0 | 0 | 1 | 0 |
Trough morning FEV1 measurements were taken pre-dose and pre-rescue bronchodilator treatment for asthma. The baseline pulmonary function measurement was defined as the measurement obtained at randomization visit (Day 1). Pulmonary function measurements (including FEV1) were obtained electronically by spirometry. All pulmonary function test data were submitted to a central reading center for evaluation. The highest FEV1 value from 3 acceptable and 2 repeatable maneuvers (maximum of 5 attempts) was used. Baseline-adjusted FEV1 AUEC(0-12wk) were calculated using the trapezoidal rule. The standardized baseline-adjusted FEV1 AUEC(0-12 wk) accommodates participants who dropped out of the study. Baseline-adjusted FEV1 AUEC(0-t weeks)/t, where t =12 weeks for patients who complete the FEV1 assessment at Week 12. For participants who dropped out early, t \<12 weeks (2, 4, or 8 weeks).
| Liters | Placebo BAI and MDI | BDP 320 mcg BAI | BDP 640 mcg BAI | BDP 320 mcg MDI | BDP 640 mcg MDI |
|---|---|---|---|---|---|
| Standardized Baseline-adjusted Trough Morning Forced Expiratory Volume in 1 Second (FEV1) Area Under the Effect Curve From Time 0 to 12 Weeks (AUEC(0-12wk) ) | 0.056 ± 0.0219 | 0.09 ± 0.0221 | 0.101 ± 0.0221 | 0.041 ± 0.0217 | 0.096 ± 0.0216 |
A hand-held peak flow meter was provided to patients at the screening visit and used to determine the morning and evening PEF throughout the course of the study. Daily trough morning PEF assessments were taken pre-dose and pre-rescue bronchodilator over the 12-week treatment period. The patient recorded the highest value of 3 measurements obtained in the morning and evening in the patient diary. Baseline in trough morning PEF is defined as the average of recorded trough morning PEF assessments over the 7-day window before randomization, including the morning assessment on Day 1 before randomization. Weekly average PEF data was generated using 7-day windows based on analysis days (before the first dose of double-blind study treatment). PEF over the 12 week treatment period was performed using a mixed-model for repeated measures (MMRM) with effects due to baseline weekly average of daily trough morning PEF, sex, age, treatment, time, and time by treatment interaction.
| Liters/minute | Placebo BAI and MDI | BDP 320 mcg BAI | BDP 640 mcg BAI | BDP 320 mcg MDI | BDP 640 mcg MDI |
|---|---|---|---|---|---|
| Change From Baseline in Weekly Average of Daily Trough Morning Peak Expiratory Flow (PEF) Over the 12-week Treatment Period Using a Mixed Model for Repeated Measures (MMRM) | -5.524 ± 2.5944 | 5.092 ± 2.5625 | 2.895 ± 2.559 | 0.480 ± 2.558 | 6.988 ± 2.5298 |
A hand-held peak flow meter was provided to patients at the screening visit and used to determine the morning and evening PEF throughout the course of the study. The patient recorded the highest value of 3 measurements obtained in the morning and evening in the patient diary. Baseline in evening PEF is defined as the average of recorded evening PEF assessments over the 7-day window before randomization. Weekly average PEF data was generated using 7-day windows based on analysis days (after the first dose of double-blind study treatment). PEF over the 12 week treatment period was performed using a mixed-model for repeated measures (MMRM) with effects due to baseline weekly average of daily evening peak PEF, sex, age, treatment, time, and time by treatment interaction.
| Liters/minute | Placebo BAI and MDI | BDP 320 mcg BAI | BDP 640 mcg BAI | BDP 320 mcg MDI | BDP 640 mcg MDI |
|---|---|---|---|---|---|
| Change From Baseline in Weekly Average of Daily Evening Peak Expiratory Flow (PEF) Over the 12-week Treatment Period Using a Mixed Model for Repeated Measures (MMRM) | -4.708 ± 2.6503 | 4.439 ± 2.6199 | 4.462 ± 2.6092 | -0.62 ± 2.6145 | 5.594 ± 2.5848 |
Change from baseline in the use of rescue medication, albuterol/salbutamol, during the treatment period offers an indication of asthma control. Baseline was defined as the average of recorded daily usage of albuterol/salbutamol inhalation aerosol over the 7 days prior to the first dose of double-blind study treatment, including the morning usage at the randomization visit. Weekly average rescue medication data was generated using 7-day windows based on analysis days (after the first dose of double-blind study treatment). Weekly average over the 12 week treatment period was performed using a mixed-model for repeated measures (MMRM) with effects due to baseline value, sex, age, time, treatment, and time-by-treatment interaction.
| number of inhalations | Placebo BAI and MDI | BDP 320 mcg BAI | BDP 640 mcg BAI | BDP 320 mcg MDI | BDP 640 mcg MDI |
|---|---|---|---|---|---|
| Change From Baseline in the Weekly Average of Total Daily (24-hour) Use of Albuterol/Salbutamol Inhalation Aerosol (Number of Inhalations) Over Weeks 1-12 Using a Mixed Model for Repeated Measures (MMRM) | 0.478 ± 0.1232 | -0.226 ± 0.1235 | -0.213 ± 0.1221 | -0.173 ± 0.1246 | -0.323 ± 0.1206 |
Asthma symptom scores are recorded in the patient's diary each morning and each evening before determining PEF and before administration of study or rescue medications. The Daytime Symptom Score (determined in the evening) has a range from 0=No symptoms during the day to 5=Symptoms so severe that I could not go to work or perform normal daily activities. The Nighttime Symptom Score (determined in the morning) has a range from 0=No symptoms during the night to 4=Symptoms so severe that I did not sleep at all. The total daily asthma symptom score is the average of the daytime and the nighttime scores (full scale is 0 - 4.5). The total daily asthma symptom score is missing if either the daytime or nighttime score is missing. Baseline was the average of recorded daily asthma symptom scores over 7 days prior to the first dose of study treatment. The weekly average was the sum of total daily asthma symptom scores over the 7 days divided by the number of non-missing assessments.
| units on a scale | Placebo BAI and MDI | BDP 320 mcg BAI | BDP 640 mcg BAI | BDP 320 mcg MDI | BDP 640 mcg MDI |
|---|---|---|---|---|---|
| Change From Baseline in the Weekly Average of the Total Daily Asthma Symptom Score Over Weeks 1-12 Using a Mixed Model for Repeated Measures (MMRM) | -0.058 ± 0.0425 | -0.207 ± 0.0417 | -0.159 ± 0.0415 | -0.247 ± 0.0417 | -0.274 ± 0.0411 |
Time to withdrawal due to meeting stopping criteria is defined as number of days elapsed from the date of the first dose of double-blind study treatment to the date of withdrawal due to meeting stopping criteria. Stopping criteria are: * FEV1 as measured at the study center is below the FEV1 stability limit value calculated at RV. * Based upon review of patient diary data, the patient has experienced any of the following during any 7-day period: * 4+ days in which the highest (of 3 efforts) am PEF fall below the PEF stability limit calculated when randomized. The patient meets with the investigator who determines whether the FEV1 is consistent with worsening asthma; * 3+ days in which 12+ inhalations/day of rescue medication were used * 2+ days in which the patient experienced a nighttime asthma symptom score of more than 2 * Clinical asthma exacerbation requiring (for example) the use of systemic corticosteroids, or the emergency room or hospitalization.
| days | Placebo BAI or MDI | BDP 320 mcg BAI | BDP 640 mcg BAI | BDP 320 mcg MDI | BDP 640 mcg MDI |
|---|---|---|---|---|---|
| Kaplan-Meier Estimates for Time to Withdrawal From Study Treatment Due to Meeting Stopping Criteria for Worsening Asthma | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
A count of participants who were withdrawn from the study due to meeting stopping criteria. Alert criteria for individual patients with worsening asthma were designed to ensure patient safety. The investigator determined whether the patient's overall clinical picture is consistent with worsening asthma and if the patient should be withdrawn from study drug treatment (but not the study) and be placed on appropriate asthma therapy in the interest of patient safety. An example of alert criteria is: * FEV1 as measured at the study center is below the FEV1 stability limit value calculated at randomization visit (Day 1). * Other criteria as defined in the protocol.
| Participants | Placebo BAI or MDI | BDP 320 mcg BAI | BDP 640 mcg BAI | BDP 320 mcg MDI | BDP 640 mcg MDI |
|---|---|---|---|---|---|
| Number of Participants Withdrawn From Study Due to Meeting Stopping Criteria for Worsening Asthma During the 12-Week Treatment Period | 15 | 3 | 3 | 5 | 1 |
Collected over - Run-In Period: Days -21 to Day 1 - Double-blind Treatment Period: Day 1 to Week 12. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BDP 320 mcg BAI | 0/106 (0%) | 1/106 (0.9%) | 9/106 (8.5%) |
| BAI 640 mcg/Day | 0/106 (0%) | 1/106 (0.9%) | 11/106 (10.4%) |
| MDI 320 mcg/Day | 0/107 (0%) | 1/107 (0.9%) | 9/107 (8.4%) |
| MDI 640 mcg/Day | 0/107 (0%) | 2/107 (1.9%) | 12/107 (11.2%) |
| Placebo BAI and MDI | 0/106 (0%) | 0/106 (0%) | 2/106 (1.9%) |
| Run-in Period Experience for Randomized Participants | 0/532 (0%) | 1/532 (0.2%) | 8/532 (1.5%) |
| Event | BDP 320 mcg BAI | BAI 640 mcg/Day | MDI 320 mcg/Day | MDI 640 mcg/Day | Placebo BAI and MDI | Run-in Period Experience for Randomized Participants |
|---|---|---|---|---|---|---|
| GastroenteritisInfections and infestations | 1/106 | 0/106 | 0/107 | 0/107 | 0/106 | 0/532 |
| HypokalaemiaMetabolism and nutrition disorders | 1/106 | 0/106 | 0/107 | 0/107 | 0/106 | 0/532 |
| Renal failure acuteRenal and urinary disorders | 1/106 | 0/106 | 0/107 | 0/107 | 0/106 | 0/532 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/106 | 1/106 | 0/107 | 0/107 | 0/106 | 0/532 |
| Abdominal painGastrointestinal disorders | 0/106 | 0/106 | 1/107 | 0/107 | 0/106 | 0/532 |
| Diverticular perforationGastrointestinal disorders | 0/106 | 0/106 | 0/107 | 1/107 | 0/106 | 0/532 |
| Gastric disorderGastrointestinal disorders | 0/106 | 0/106 | 1/107 | 0/107 | 0/106 | 0/532 |
| Pancreatitis acuteGastrointestinal disorders | 0/106 | 0/106 | 1/107 | 0/107 | 0/106 | 0/532 |
| CholelithiasisHepatobiliary disorders | 0/106 | 0/106 | 1/107 | 0/107 | 0/106 | 0/532 |
| Pharyngeal abscessInfections and infestations | 0/106 | 0/106 | 0/107 | 1/107 | 0/106 | 0/532 |
| Event | BDP 320 mcg BAI | BAI 640 mcg/Day | MDI 320 mcg/Day | MDI 640 mcg/Day | Placebo BAI and MDI | Run-in Period Experience for Randomized Participants |
|---|---|---|---|---|---|---|
| Oral candidiasisInfections and infestations | 5/106 | 10/106 | 3/107 | 9/107 | 0/106 | 7/532 |
| Upper respiratory tract infectionInfections and infestations | 4/106 | 1/106 | 7/107 | 4/107 | 2/106 | 1/532 |
Patients administered 4 inhalations from each of the 2 devices twice daily as per the double dummy study design: 1 treatment device or placebo and 1 placebo device for a total of 8 inhalations each time.
| Age, Categorical(Participants) | Placebo BAI and MDI | BDP 320 mcg BAI | BDP 640 mcg BAI | BDP 320 mcg MDI | BDP 640 mcg MDI | Total |
|---|---|---|---|---|---|---|
| <=18 years | 4 | 5 | 7 | 4 | 6 | 26 |
| Between 18 and 65 years | 94 | 86 | 92 | 93 | 92 | 457 |
| >=65 years | 8 | 15 | 7 | 10 | 9 | 49 |
| Sex: Female, Male(Participants) | Placebo BAI and MDI | BDP 320 mcg BAI | BDP 640 mcg BAI | BDP 320 mcg MDI | BDP 640 mcg MDI | Total |
|---|---|---|---|---|---|---|
| Female | 68 | 69 | 67 | 65 | 66 | 335 |
| Male | 38 | 37 | 39 | 42 | 41 | 197 |
| Race (NIH/OMB)(Participants) | Placebo BAI and MDI | BDP 320 mcg BAI | BDP 640 mcg BAI | BDP 320 mcg MDI | BDP 640 mcg MDI | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 6 | 3 | 5 | 2 | 2 | 18 |
| Black or African American | 27 | 18 | 14 | 16 | 24 | 99 |
| White | 73 | 85 | 87 | 89 | 81 | 415 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
Showing the first 100 of 131 sites across 4 countries. Choose a country and city above to see the rest.
The record gives a start of Dec 2013, a primary completion of Nov 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2018, 3 years 2 months after primary completion. A results delay was requested in May 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Beclomethasone
Teva Branded Pharmaceutical Products R&D, Inc. →